Mosunetuzumab in untreated FL and MZL: a response-adapted trial
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses the early results of a response-adapted trial investigating the safety and efficacy of mosunetuzumab in untreated follicular lymphoma (FL) and marginal zone lymphoma (MZL). This bispecific antibody is already approved in the relapsed/refractory (R/R) FL setting, and this study provides preliminary evidence that high complete response (CR) rates are seen after 8 cycles in treatment-naïve patients, with a favorable safety profile. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Смотрите видео Mosunetuzumab in untreated FL and MZL: a response-adapted trial онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 05 Март 2024, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 142 раз и оно понравилось 3 людям.